Metformin Attenuates Liver Fat Content: Finding from Schizophrenia Patients with Olanzapine-induced Weight Gain
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective: This study was performed to evaluate the efficacy of metformin on liver fat content (LFC) in first episode schizophrenia patients with olanzapine-induced weight gain, and the relationship between the change of LFC and the other metabolic indices. Methods: In a double-blind study, the clinically stable inpatients with first-episode schizophrenia under olanzapine monotherapy who gained more than 7% of their baseline weight were randomly assigned to two groups; one with olanzapine plus metformin (1,000 mg/day) (metformin group) and the other with olanzapine plus placebo (placebo group) for 16 weeks. All patients continued to maintain the original olanzapine dosage. LFC was measured by magnetic resonance imaging at baseline and at the end of 16 weeks, respectively. At the same time, glucose and lipid metabolism, homeostasis model assessment of insulin resistance index (HOMA-IR) were measured respectively, analyzing the correlation between the change value of LFC and other indicators. Results: Over the 16-week study period, LFC value in metformin group decreased compared with baseline. LFC change across the 16-week treatment period was −2.91% for the metformin group and 0.59% for the placebo group, with a between-group difference of −3.5% (95% confidence interval, −6.08 to −0.93; p = 0.009). Compared to baseline, in the metformin group, triglyceride and HOMA-IR reduced significantly, while high density lipoprotein cholesterol increased significantly at weeks 16. There was positive correlation between LFC changes and triglycerides, HOMA-IR changes significantly. Conclusion: Metformin can significantly attenuate LFC in schizophrenia patients with olanzapine-induced weight gain. It may be related to the improvement of the part of the glucolipid metabolic indices
Abstract
Objective: This study was performed to evaluate the efficacy of metformin on liver fat content (LFC) in first episode schizophrenia patients with olanzapine-induced weight gain, and the relationship between the change of LFC and the other metabolic indices. Methods: In a double-blind study, the clinically stable inpatients with first-episode schizophrenia under olanzapine monotherapy who gained more than 7% of their baseline weight were randomly assigned to two groups; one with olanzapine plus metformin (1,000 mg/day) (metformin group) and the other with olanzapine plus placebo (placebo group) for 16 weeks. All patients continued to maintain the original olanzapine dosage. LFC was measured by magnetic resonance imaging at baseline and at the end of 16 weeks, respectively. At the same time, glucose and lipid metabolism, homeostasis model assessment of insulin resistance index (HOMA-IR) were measured respectively, analyzing the correlation between the change value of LFC and other indicators. Results: Over the 16-week study period, LFC value in metformin group decreased compared with baseline. LFC change across the 16-week treatment period was −2.91% for the metformin group and 0.59% for the placebo group, with a between-group difference of −3.5% (95% confidence interval, −6.08 to −0.93; p = 0.009). Compared to baseline, in the metformin group, triglyceride and HOMA-IR reduced significantly, while high density lipoprotein cholesterol increased significantly at weeks 16. There was positive correlation between LFC changes and triglycerides, HOMA-IR changes significantly. Conclusion: Metformin can significantly attenuate LFC in schizophrenia patients with olanzapine-induced weight gain. It may be related to the improvement of the part of the glucolipid metabolic indices
참고문헌 (34)
- Coccurello R, "Potential mechanisms of atypical antipsychotic-induced metabolic derangement : clues for understanding obesity and novel drug design", Pharmacol Ther, 127, pp.210~251 (2010)
- De Hert M, "Metabolic and cardiovascular adverse effects associated with antipsychotic drugs", Nat Rev Endocrinol, 8, pp.114~126 (2011)
- Henderson DC, "Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality : results of a 10-year naturalistic study", J Clin Psychiatry, 66, pp.1116~1121 (2005)
- Eckel RH, "The metabolic syndrome", Lancet, 365, pp.1415~1428 (2005)
- Howland RH, "A"glucose eater"drug as a therapeutic agent in psychiatry", J Psychosoc Nurs Ment Health Serv, 51, pp.13~16 (2013)
- Wang M, "Metformin for treatment of antipsychotic-induced weight gain : a randomized, placebo-controlled study", Schizophr Res, 138, pp.54~57 (2012)
- Wu RR, "Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia : a double-blind, randomized, placebo-controlled study", Am J Psychiatry, 169, pp.813~821 (2012)
- Ehret M, "The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents : a meta-analysis", J Clin Psychiatry, 71, pp.1286~1292 (2010)
- Praharaj SK, "Metformin for olanzapine-induced weight gain : a systematic review and metaanalysis", Br J Clin Pharmacol, 71, pp.377~382 (2011)
- Newall H, "Efficacy of metformin for prevention of weight gain in psychiatric populations : a review", Int Clin Psychopharmacol, 27, pp.69~75 (2012)
- Jarskog LF, "Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder", Am J Psychiatry, 170, pp.1032~1040 (2013)
- Geerling JJ, "Metformin lowers plasma triglycerides by promoting VLDL-triglyceride clearance by brown adipose tissue in mice", Diabetes, 63, pp.880~891 (2014)
- D’Adamo E, "Central role of fatty liver in the pathogenesis of insulin resistance in obese adolescents", Diabetes Care, 33, pp.1817~1822 (2010)
- Byrne CD, "Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease : implications for cardiovascular disease", Arterioscler Thromb Vasc Biol, 34, pp.1155~1161 (2014)
- Byrne CD, "Ectopic fat, insulin resistance and non-alcoholic fatty liver disease", Proc Nutr Soc, 72, pp.412~419 (2013)
- Byrne CD, "Dorothy Hodgkin Lecture 2012 : non-alcoholic fatty liver disease, insulin resistance and ectopic fat : a new problem in diabetes management", Diabet Med, 29, pp.1098~1107 (2012)
- Chan DC, "Measurement of liver fat by magnetic resonance imaging : relationships with body fat distribution, insulin sensitivity and plasma lipids in healthy men", Diabetes Obes Metab, 8, pp.698~702 (2006)
- Kotronen A, "Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes", Gastroenterology, 135, pp.122~130 (2008)
- Haufe S, "Cardiorespiratory fitness and insulin sensitivity in overweight or obese subjects may be linked through intrahepatic lipid content", Diabetes, 59, pp.1640~1647 (2010)
- Linder K, "Relationships of body composition and liver fat content with insulin resistance in obesity-matched adolescents and adults", Obesity(Silver Spring), 22, pp.1325~1331 (2014)
- Lichtenstein AH, "Summary of American Heart Association diet and lifestyle recommendations revision 2006", Arterioscler Thromb Vasc Biol, 26, pp.2186~2191 (2006)
- Parikh RM, "Index of central obesity-a novel parameter", Med Hypotheses, 68, pp.1272~1275 (2007)
- Cassidy FH, "Fatty liver disease : MR imaging techniques for the detection and quantification of liver steatosis", Radiographics, 29, pp.231~260 (2009)
- Bugianesi E, "A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease", Am J Gastroenterol, 100, pp.1082~1090 (2005)
- Yang J, "Long-term metformin treatment stimulates cardiomyocyte glucose transport through an AMP-activated protein kinase-dependent reduction in GLUT4 endocytosis", Endocrinology, 147, pp.2728~2736 (2006)
- Rector RS, "Non-alcoholic fatty liver disease and the metabolic syndrome : an update", World J Gastroenterol, 14, pp.185~192 (2008)
- Chen CH, "Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine", Prog Neuropsychopharmacol Biol Psychiatry, 32, pp.925~931 (2008)
- Ellinger LK, "Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain", Ann Pharmacother, 44, pp.668~679 (2010)
- Maayan L, "Management of antipsychotic-related weight gain", Expert Rev Neurother, 10, pp.1175~1200 (2010)
- Wulffelé MG, "The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus : a systematic review", J Intern Med, 256, pp.1~14 (2004)
- Li Y, "AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice", Cell Metab, 13, pp.376~388 (2011)
- Chen WL, "Metformin regulates hepatic lipid metabolism through activating AMP-activated protein kinase and inducing ATGL in laying hens", Eur J Pharmacol, 671, pp.107~112 (2011)
- Isla Pera P, "Chronic complications of diabetes mellitus. Recommendations from the American Diabetes Association 2011. Prevention and management", Rev Enferm, 35, pp.46~52 (2012)
- Targher G, "Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2diabetic patients", Diabetes Care, 30, pp.1212~1218 (2007)